Mark J Alexander Selected Research

Growth Differentiation Factors

12/2022

Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark J Alexander Research Topics

Disease

4	Anemia 01/2020 - 01/2013
3	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2020 - 01/2013
1	Pulmonary Arterial Hypertension 12/2022
1	Inflammation (Inflammations) 12/2022
1	Muscle Weakness 01/2021
1	Disease Progression 01/2021
1	Neuromuscular Diseases (Neuromuscular Disease) 01/2019
1	beta-Thalassemia (Cooley's Anemia) 06/2014
1	Splenomegaly 06/2014
1	Iron Overload 06/2014
1	Thalassemia 06/2014
1	Hemolysis 06/2014
1	Hyperplasia 04/2014
1	Neoplasms (Cancer) 01/2013
1	Neoplasm Metastasis (Metastasis) 01/2013
1	Multiple Myeloma 01/2013
1	Bone Diseases (Bone Disease) 01/2013
1	Carcinogenesis 01/2013
1	Osteolysis 01/2013
1	Malnutrition (Nutritional Deficiencies) 09/2003

Drug/Important Bio-Agent (IBA)

4	LigandsIBA 01/2020 - 04/2014
3	Proteins (Proteins, Gene)FDA Link 12/2022 - 09/2003
3	luspaterceptIBA 01/2020 - 04/2014
3	Activin Receptors (Activin Receptor)IBA 01/2020 - 01/2013
3	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2019 - 04/2014
3	Erythropoietin FDA Link 06/2014 - 01/2013
2	ACE-011IBA 12/2022 - 01/2013
2	Biological ProductsIBA 01/2021 - 01/2020
1	Activins (Activin)IBA 12/2022
1	Growth Differentiation FactorsIBA 12/2022
1	activin receptor type II-A (activin A receptor, type II)IBA 12/2022
1	Vasodilator Agents (Vasodilators)IBA 01/2021
1	DystrophinIBA 01/2021
1	Glycoproteins (Glycoprotein)IBA 01/2019
1	FollistatinIBA 01/2019
1	GlobinsIBA 06/2014
1	activin receptor type II-BIBA 06/2014
1	IronIBA 06/2014
1	Reactive Oxygen Species (Oxygen Radicals)IBA 06/2014
1	LY-2157299IBA 01/2013
1	Anabolic AgentsIBA 01/2013
1	Messenger RNA (mRNA)IBA 09/2003

Therapy/Procedure

1	Therapeutics 01/2021
1	Drug Therapy (Chemotherapy) 01/2013